Summary
Prevalence of pituitary mass lesions
The frequency of detection of mass lesions in the pituitary depends on the sensitivity of the relevant imaging technique (box 1). Autopsy studies of almost 10 000 subjects not suspected of having pituitary disease whilst alive revealed a startling 11% prevalence of pituitary adenomas less than 10 mm in diameter (microadenomas).1 Interestingly, only three macroadenomas (more than 10 mm diameter) were uncovered in this large group of subjects. The inevitable conclusions are that microadenomas are common in asymptomatic subjects and that they rarely progress to macroadenomas, which presumably declare their presence with symptoms of hypopituitarism or those of a pituitary mass lesion. Initial computed tomography (CT) studies of asymptomatic subjects supported the post-mortem findings as discrete areas of low density were found in 3.7-20% of 'normal' pituitaries.' The most sensitive pituitary imaging technique available, magnetic resonance imaging (MRI), has recently been subjected to the same scrutiny. Review of pituitary MRI scans of 100 adults with normal baseline endocrine parameters revealed that 10% have 3-6 mm areas of decreased signal intensity following contrast administration, compatible with pituitary microadenomas.2 The 'pituitary incidentaloma', the offspring of modem imaging technology, has thus come of age and requires rational and reasoned evaluation by clinicians. 3 
Diagnostic considerations
The differential diagnosis ofa mass lesion in the pituitary region is extensive (box 2) and although many of the entities listed are distinctly uncommon, they may require specific therapy. A patient harbouring a germinoma, for instance, would benefit from pituitary radiation as primary therapy, while a patient with a carotid siphon aneurysm in the pituitary region would be placed at substantial risk by pituitary exploration. An encroachment on the visual pathways on MRI. Furthermore, evidence of hypopituitarism should be sought both clinically and biochemically 7 (box 3). A patient with a macroadenoma, other than a macroprolactinoma, producing a visual field deficit or hypopituitarism should be considered for pituitary surgery. The second concern pertaining to both micro-and macroadenomas, is the possibility of hormone excess. Each patient should therefore be evaluated clinically for evidence of Cushing's syndrome, acromegaly and prolactinoma, as these conditions have been shown to be associated with substantial morbidity and, for the first two, increased mortality.8-'0 A patient with biochemical evidence of GH, cortisol or rarely TSH hypersecretion should be offered pituitary surgery, although the patient's age and general condition will clearly affect the decision. Prolactinomas are, however, successfully treated medically with a dopamine agonist in the majority of patients.10
Natural history of untreated pituitary adenomas If we accept the notion that most patients with a pituitary incidentaloma and evidence ofhormone excess require definitive therapy, what are we to make ofthe majority of patients with a hormonally silent pituitary adenoma? Evidence of hypopituitarism or a reduction in vision constitute reasonable indications for pituitary surgery as the procedure may reverse or improve both abnormalities."
The approach to incidental pituitary adenomas without hormone excess, hypopituitarism or mass effects depends on the natural history of these lesions if left untreated. Several recent studies have addressed this important issue (box 4).12,13 The study by Reincke et al prospectively followed 14 patients with pituitary incidentalomas (seven micro-and seven macroadenomas) treated conservatively for a median of 22 months. Three patients had biochemical evidence of hypopituitarism at baseline assessment. In 13 patients there was no change mn the endocrine status during follow-up, while a single subject had a further decrease in serum gonadotropin levels. Tumour volume remained unaltered in 10 patients, although three patients (two macro-and one microadenomas) had an increase in tumour diameter of between 3 and 6 mm without any deterioration in visual acuity, while one subject had a 4-mm reduction in diameter. The results of this small study suggest that conservative treatment of asymptomatic incidental pituitary micro-and even macroadenomas may be safely contemplated. A more recent series from Donovan et al provides further reassurance. After a median follow-up of approximately six years, none of 15 micro-and four of 16 macroadenomas enlarged, only two with any complications. The patient who developed visual impairment harboured a craniopharyngioma. The concept is thus evolving that micro-incidentalomas rarely enlarge, and that in a patient with a macro-incidentaloma a reasonable approach would be to repeat scans periodically, reserving surgery for patients manifesting tumour growth or hypopituitarism. This approach is based on preliminary data and may be modified as clinical experience accumulates.
Endocrine evaluation
The decision to screen biochemically for pituitary hormone excess, even in the abscence of clinical indicators, is supported by recent reviews of the topic.3'5 The argument advanced by the protagonists of biochemical screening is the detection of a single 'silent' case of acromegaly in a series of 18 patients with pituitary incidentalomas.12 A recent study of 31 adults with pituitary incidentalomas suggests, however, that biochemical screening of subjects with no clinical evidence of an endocrine disorder may be fruitless.'3 The subjects were followed for a mean of 6.4 years after an initial clinical evaluation excluded an endocrinopathy (no routine biochemical evaluation for Cushing's syndrome or acromegaly was performed) and no patient subsequently developed a syndrome of hormone excess. The available data relating to the necessity for routine biochemical screening for acromegaly and Cushing's syndrome are thus limited and contradictory. Our current approach is to exclude these two conditions definitively by means of simple screening tests, although we concede that evidence may accumulate in the future proving this to be over cautious.
PROLACTINOMAS
The mere presence ofhyperprolactinaemia in a patient with a microprolactinoma does not necessarily demand definitive therapy (figure 3). Firstly, two or three measurements of prolactin are indicated to ensure the hyperprolactinaemia is sustained. Secondly, the common secondary causes of elevated prolactin concentrations should be considered (box 5) as a small lesion evident on pituitary imaging may be unrelated to the hyperprolactinaemia. If the hyperprolac- 
